Innate Pharma S.A.

Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma third quarter 2024 business update and financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, then the number one on your telephone keypad. To withdraw your question, press star one again. I would now like to turn the conference over to Henry Wheeler, Vice President, Investor Relations. Please go ahead.

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our Q3 2024 business updates and financial results. We look forward to highlighting the progress made during the year to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website. On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risk and uncertainties that may cause actual results to differ from those forecasted. Slide three, on today's call, we are very pleased to be joined by Jonathan Dickinson, our new Chief Executive Officer. Jonathan is a seasoned healthcare professional and joins from Insights. He has a strong background in oncology and previous roles include Ariad, BMS, Roche, and Novartis. On the next slide, to cover today's agenda, after an introduction from Jonathan, Sonia Quarantino, our Chief Medical Officer, will cover updates on Nucutimab, IPH6501, and 4502. We will then hand to Yanis Moral, Chief Operating Officer, who will then discuss our ANCET platform, ADC-CITC, and MonolizMAP updates. Arvind Sood, EVP, US Operations, will wrap and close, and we'll also have Frederick Lombard, our CFO, on the line for questions. Jonathan, I now hand the call over to you.

Thank you, Henry. Good morning and good afternoon to everybody on the call. I'm very excited to join Innate Pharma, a company which is at the forefront of cutting edge science in oncology. The innovative work being done at Innate is truly inspiring and world class, and I'm looking forward to using my extensive oncology experience to shape the Innate portfolio to maximize the future commercial potential and drive the next chapter of Innate's exciting journey. I look forward to meeting with as many of you as possible in the coming weeks. Turning to slide six, I would like to remind you of our strategy. As a company with proprietary assets in early clinical stages and partnered assets in early to later stages, Our strategy involves leveraging our world-class expertise to develop first and best in class antibody-based therapies for cancer. Our current business model centers around the three priorities highlighted in slide six, where we look to drive value from our proprietary R&D efforts through our well-established late stage partnerships. Our ambition is to take our proprietary assets further along the clinical development pathway, and thereby transform cancer care through a strong pipeline of novel, differentiated antibodies. The first of these priorities is our lead proprietary asset, leucutamab, where we look to create near-term value. Leucutamab is in development for T-cell lymphoma, with the top-line phase II CTCL data already presented. Based on this data, we have had recent interactions with FDA. Sonia will cover this feedback later in today's presentation, and we're now assessing the best path forward to maximize the potential of Leucutamab, including a potential partnership. Second, we continue to fuel our pipeline and create longer-term value by leveraging our antibody engineering capabilities to develop innovative molecules with a primary focus on our multi-specific NK cell engager proprietary platform called Anket. We're pleased to see continued progress with Sanofi presenting various updates for the lead Anket program, IPH61-SAR579. We're pleased to see our lead proprietary Anket, IP65, continue to progress in phase one. As we develop antibody targets for our ANCHAIR platform, we recognize that some of these targets may be better suited to an ADC approach. We will illustrate further details of our ADC pipeline today, where our lead asset, IPH45, has now received IND clearance from FDA and will start phase one trials by Q1 next year. Finally, we're building strong and sustainable foundations for our business by developing value creating partnerships across industry and academia monolizumab which is partnered with az is a good example of these partnerships and the product as part of this collaboration is advancing well in phase three trials in lancaster turning to slide seven this shows a summary of our pipeline which highlights how we continue translate our science into a robust portfolio of proprietary and partnered assets. When the IPH45 Phase 1 study starts by Q1 next year, we will have eight clinical assets. The slide also illustrates how we are executing against our strategy with our lead proprietary assets, the Kutumet, Hankhet, and emerging ADCs, and which is supported by partner products from late to early stage with AstraZeneca and Sanofi. We anticipate a series of potential clinical data readouts and catalysts in the short to mid-term as we leverage our R&D engine and scientific know-how to create a sustainable business. Moving to slide eight, which highlights our Q4 conference activity at CIDC and ASH. At the CIDC meeting last week, we presented further clinical data on our next generation CD20 targeting Yanket IPH65, as well as preclinical data on our Nectin-4 targeting ADC IPH45, which will be covered by Yanis later in today's presentation. At ASH, we were pleased to see, or we're pleased to see, that the Kutumat data was accepted for an oral presentation, highlighting follow-up on the telemark trial in relapsed recurrent spontaneous T-cell lymphoma, as well as a poster on translational analysis. I would like to now pass the call over to Sonia, who will review the progress made with our clinical portfolio. Sonia.